Brent Sabatini Sells 1,530 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,530 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $7.79, for a total transaction of $11,918.70. Following the sale, the chief accounting officer directly owned 47,872 shares in the company, valued at $372,922.88. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Vir Biotechnology Price Performance

Shares of VIR opened at $7.68 on Friday. The company has a market cap of $1.07 billion, a PE ratio of -2.13 and a beta of 1.69. The firm has a 50-day moving average of $6.71 and a 200-day moving average of $5.90. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $9.97.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays set a $26.00 target price on Vir Biotechnology in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VIR. AQR Capital Management LLC raised its stake in shares of Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Vir Biotechnology in the first quarter worth about $359,000. Goldman Sachs Group Inc. lifted its holdings in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after buying an additional 225,544 shares in the last quarter. Woodline Partners LP boosted its position in shares of Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after acquiring an additional 331,701 shares during the period. Finally, Focus Partners Wealth grew its stake in Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after acquiring an additional 2,566 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.